Barriers to Progress: Why Personalized Medicine Hasn't Developed for Chronic Conditions

Chronic conditions—asthma, hypertension, diabetes, depression, and others—are widely prevalent and have a significant impact on long-term healthcare costs. Diagnostic targeting of drug therapies in treatment may improve response rates and adherence, producing both clinical and economic benefits. But first, some current care delivery and infrastructure paradigms have to change.

Key aspects of the community care delivery model, including test reporting and clinical practice management, tend to act as barriers to targeting chronic disease therapy.  For diagnostic drug targeting to gain acceptance in the treatment of chronic diseases, manufactures will need to address these issues—ensuring short-term economic and practice incentives align with long-term clinical benefits

Get the Brief

    Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.